天津医药

• 论著 •    

罗格列酮对2型糖尿病患者血清visfatin和ghrelin水平的影响

邓震亭   

  1. 天津中医药大学第一附属医院药剂部
  • 收稿日期:2010-09-21 修回日期:2011-05-10 出版日期:2012-01-15 发布日期:2012-01-15
  • 通讯作者: 邓震亭

The effect of rosiglitazone on the level of serum visfatin and ghrelin in patients with type 2 diabetes

  • Received:2010-09-21 Revised:2011-05-10 Published:2012-01-15 Online:2012-01-15

PDF (PC)

1940

摘要： 【摘要】目的 观察罗格列酮对2型糖尿病患者内脂素(visfatin)和生长激素释放肽(ghrelin)水平的影响。方法 72例2型糖尿病患者随机分为对照组和罗格列酮治疗组，每组36例。治疗组给予罗格列酮4 mg/d，治疗16周。结果 治疗l6周后，两组的血压、血糖、甘油三酯(TG)和胰岛素抵抗指数(HOMA-IR)均明显下降，而罗格列酮组降低更明显，与对照组相比，差异有统计学意义。另外，与治疗前相比，治疗组的高密度脂蛋白胆固醇(HDL-c)和血清ghrelin水平升高，内脂素水平明显下降；而对照组的HDL-c、血清ghrelin和内脂素水平，在治疗前后无明显变化。相关性分析表明，血清内脂素水平与体质指数(BMI)、空腹血糖(FPG)、HOMA-IR呈显著正相关；而ghrelin水平与BMI、FPG、TG、HOMA-IR呈负相关。结论 罗格列酮具有升高血清ghrelin和降低内脂素的作用，可能与其改善胰岛素抵抗的机制有关。

关键词: 罗格列酮, 2型糖尿病, 内脂素, 生长激素释放肽

Abstract: 【Abstract】Objective To investigate the effect of rosiglitazone on the level of serum visfatin and ghrelin in type 2 diabetes patients．Methods 72 patients with type 2 diabetes were randomly divided into control group and rosiglitazone treated group (36 patients in each group). And patients in rosiglitazone treated group were treated with rosiglitazone (4 mg/d) for 16 weeks. Results After treatment for 16 weeks, the levels of blood pressure, blood glucose, triglyceride (TG) and homeostasis model assessment-insulin resistance (HOMA-IR) were significantly reduced in these two groups. And those in rosiglitazone treated group reduced much more compared with the control group. Increased level of HDL-c and serum ghrelin, and reduced level of serum visfatin were observed in rosiglitazone treated group compared with those before treatment. However, there were no significant differences in the level of those characteristics between before and after treatment in the control group. Pearson analysis shows that the level of serum visfatin was positively associated with body mass index (BMI), fasting plasma glucose (FPG) and HOMA-IR. And the level of serum ghrelin was negatively associated with BMI, FPG, TG and HOMA-IR. Conclusions Rosiglitazone can result in elevated level of serum ghrelin and reduced level of serum visfatin in patients with type 2 diabetes．And this may be associated with the mechanism of improving insulin resistance.

Key words: rosiglitazone, type 2 diabetes, visfatin, ghrelin